Develops medical technology for women's health: diagnostic systems, screening and imaging technologies as well as gynecological treatment systems.
Hologic Deutschland GmbH
Berlin · Vienna · Cham · Lausanne · ZaventemNew on Amplifa
About Hologic Deutschland
Hologic Deutschland GmbH is the German headquarters of Hologic, a medical technology company founded in 1985, based in Berlin. The company offers systems and solutions for women's health, including molecular diagnostics systems (Panther, Panther Fusion), liquid-based cytology (ThinPrep), digital mammography and tomosynthesis (3Dimensions), bone densitometry (Horizon DXA), specimen radiography systems (Faxitron Trident HD, Faxitron Path) as well as gynecological treatment and surgical systems such as NovaSure, MyoSure, Fluent and LOCalizer. The portfolio ranges from sample collection to diagnosis and also includes AI-based software solutions such as Genius AI, 3DQuorum and Quantra. Hologic is active in more than 36 countries, employs around 7000 people worldwide and holds over 4100 patents. In Germany, Austria and Switzerland, customers are supported, among other things, through technical support, training, webinars (HologicEd) and order processing (eOrders).
- Site
- Berlin
- Processes
- Molecular diagnostics (RT-PCR / TMA assays), Liquid-based cytology (ThinPrep), Digital cytology / digital pathology (AI-based), Impedance-controlled endometrial ablation (NovaSure), Hysteroscopic morcellation of intrauterine tissue (MyoSure), Wireless RFID localization of breast lesions (LOCalizer), Specimen radiography (Faxitron Trident HD), Bone densitometry / DXA (Horizon DXA)
- Materials
- Clinical samples (nasal swab, ESwab), Whole blood, plasma, Beryllium (X-ray window 200 μm), Amorphous selenium (detector material), Tungsten (anode material), Ceramic (detector array), Lead glass RD30 (0.5 mm Pb equiv.), Molecular diagnostics (RT-PCR / TMA assays)
- Certificates
- NovaSure PMA approval (FDA, P010013), CE marking for STI tests
- Founded
- 1985
- Employees
- 7000
- Industries
- Medical technology, Women's health/Gynecology, Laboratory diagnostics/Molecular diagnostics, Breast cancer screening/Mammography, Bone densitometry (DXA/Osteoporosis), Transplantation diagnostics
- 01
Sample collection (collection kits)
- 02
Molecular diagnostics (RT-PCR/TMA assays on Panther systems)
- 03
Liquid-based cytology (ThinPrep)
- 04
Digital cytology and pathology (Genius)
- 05
Clinical decision support (AI-based software)
- 06
Customer service, training and technical support
Technologies and Applications
Molecular diagnostics (RT-PCR / TMA assays)
Detection of HPV, SARS-CoV-2, CT/NG, HIV-1, HCV, HBV, CMV, EBV, BKV, MRSA and GI pathogens from clinical samples.
Liquid-based cytology (ThinPrep)
Processing of cervical swabs for cervical cancer screening.
Dual-energy X-ray absorptiometry (DXA)
Measurement of bone mineral density and body composition with ceramic detector array (OnePass).
Bipolar radiofrequency ablation (NovaSure)
Impedance-controlled endometrial ablation with 4-electrode array and shut-off at 50 ohms.
Hysteroscopic morcellation (MyoSure)
Mechanical removal of polyps, myomas and retained placental tissue while preserving the uterus.
Specimen radiography (Faxitron Trident HD / Path)
High-resolution X-ray imaging of biopsy and surgical specimens with selenium detector technology.
Wireless RFID localization (LOCalizer)
Real-time distance measurement for localization of non-palpable breast lesions with RFID mini-tag.
Locations
Berlin
DEGerman headquarters (Kaiserin-Augusta-Allee 112/113)
Vienna
ATHologic Austria GmbH (Weyringergasse 6)
Cham
CHHologic Medicor Suisse GmbH (Gewerbestr. 10)
Lausanne
CHHologic Suisse SA (c/o World Trade Center, Av. de Gratta-Paille 2)
Zaventem
BEHologic BV, European representative office (Da Vincilaan 5)
Industries
Processes & technical limits
| Processes | Tolerance | Max. part | Weight | Lot size | Materials |
|---|---|---|---|---|---|
| Molecular diagnostics (RT-PCR / TMA assays)Testing | – | – | – | – | Clinical samples (nasal swabs, blood, plasma, whole blood), Detection of HPV, SARS-CoV-2, CT/NG, HIV-1, HCV, HBV, CMV, |
| Liquid-based cytology (ThinPrep)Testing | – | – | – | – | Cervical swabs |
| Digital cytology / digital pathology (AI-based)Testing | – | – | – | – | – |
| Impedance-controlled endometrial ablation (NovaSure)Surface | Ablation time averaging 90 seconds; endpoint 50 ohms | – | – | – | Endometrium (uterine lining) |
| Hysteroscopic morcellation of intrauterine tissue (MyoSure)Machining | – | – | – | – | Polyps ≤ 1 cm / ≤ 3 cm, myomas ≤ 3 cm / ≤ 5 cm, |
| Wireless RFID localization of breast lesions (LOCalizer)Testing | – | – | – | – | Breast tissue |
| Specimen radiography (Faxitron Trident HD)Testing | – | – | – | – | Biopsy/surgical specimens |
| Bone densitometry / DXA (Horizon DXA)Testing | – | – | – | – | Bone, Body composition (fat/muscle tissue) |
| Radiofrequency ablation (bipolar RF energy, 4-electrode array)Surface | – | – | – | – | Uterine tissue |
18 Anlagen & Maschinen
| Machine | Manufacturer / model | Quantity | Working area | Year built | Site |
|---|---|---|---|---|---|
| Molecular diagnostics system | Hologic Panther® System | – | – | – | – |
| Molecular diagnostics system | Hologic Panther Fusion® System | – | Up to 120 samples simultaneously; up to 335 results in 8 h | – | – |
| Digital mammography system | Hologic 3Dimensions™ | – | – | – | – |
| Specimen radiography system | Faxitron (Hologic) Trident® HD | – | Detector 16 x 18 cm; 20-50 kV, 1 mA, up to 20 mAs; dimensions 168 x 61 x 66 cm; 132 kg | – | – |
| DXA system (dual-energy X-ray absorptiometry) | Hologic Horizon™ DXA | – | OnePass™ ceramic detector array, fan beam; patient weight up to 227 kg (up to 204 kg) | – | – |
| Ablation controller | Hologic NovaSure® Controller / V5 | – | AccuSheath 6 mm outer diameter; bipolar RF energy, 4-electrode array | – | – |
| Hysteroscopic morcellation unit | Hologic MyoSure MANUAL / LITE / REACH / XL | – | Polyps ≤ 1 cm (MANUAL/LITE), polyps ≤ 3 cm, myomas ≤ 3 cm (REACH), myomas ≤ 5 cm, retained | – | – |
| Hysteroscope | Hologic Omni® Hysteroscope Suite (0°/30°) | – | Working length 200 mm, 5 Fr seal, small oval diameter | – | – |
| Fluid management system | Hologic Fluent® | – | Dual-scale technology, fluid deficit ± 50 ml; IV pole for two 3L bags | – | – |
| Wireless RFID localization system | Hologic LOCalizer™ System | – | RFID mini-tag, reader, disposable pen-sized probe, real-time distance measurement | – | – |
| Cytology processor | Hologic ThinPrep® 5000 Processor / Autoloader | – | ≈ 3 min per sample; ≈ 80,000 samples p. a.; W x H x D: 137 x 145 x 71 cm; capacity 64 samples, | – | – |
| Cytology processor (benchtop) | Hologic ThinPrep® T5000 Benchtop | – | ≈ 2.4 min per sample; ≈ 40,000 samples p. a.; 86 x 56 x 66 cm | – | – |
| Cytology processor | Hologic ThinPrep® Genesis | – | ≈ 2.4 min per slide; ≈ 25 samples in 1 h; 48 x 58 x 36 cm | – | – |
| Transfer system | Hologic ThinPrep® Integrated Imager Transfer | – | ≈ 1.8 min per transfer vial; ≈ 34 transfer vials per h; 80 x 65 x 71 cm | – | – |
| Transfer system | Hologic TomCat™ | – | ≈ 90 s per sample; ≈ 300 samples in 8 h; walkaway ≈ 1 h 36 min; 109.2 x 76.2 x 71.1 cm | – | – |
| Digital imager / diagnostics system | Hologic Genius™ Digital Diagnostics System | – | ≈ 3.3 min per slide & transfer vial; ≈ 18 per h; 56 x 46 x 68 cm | – | – |
| Digital imager | Hologic ThinPrep® Integrated Imager | – | ≈ 90 s per slide; ≈ 180 slides in 8 h; walkaway up to 6 h; 122 x 175 x 81.5 cm | – | – |
| Digital Imager Review Station | Hologic Digital Imager Review Station | – | on average 2.5 min per slide; ≈ 180 slides in 8 h | – | – |
Additional services
Quality and Evidence
The clinical performance of the solutions is demonstrated by hundreds of peer-reviewed studies; the NovaSure procedure has been FDA-approved since 2001 (PMA P010013). The systems comply with the major clinical guidelines, including the BI-RADS Atlas (ACR).
| Evidence | Berlin |
|---|---|
| NovaSure PMA approval (FDA, P010013) | |
| CE marking for STI tests |
History
- 1985
Foundation of Hologic
- 2001
PMA P010013 approval of the NovaSure procedure (basis for over 20 years of experience and evidence)
- 2023
Inclusion of NovaSure in the EBM effective April 1, 2023 following a positive IQWiG assessment
- 2025
Inclusion of NovaSure in the hybrid DRGs (N25N) effective January 1, 2025